Alzheimer’s disease (AD) is the most common type of dementia. Its diagnosis and progression detection have been intensively studied. Nevertheless, research studies often have little effect on clinical practice mainly due to the following reasons: (1) Most studies depend mainly on a single modality, especially neuroimaging; (2) diagnosis and progression detection are usually studied separately as two independent problems; and (3) current studies concentrate mainly on optimizing the performance of complex machine learning models, while disregarding their explainability. As a result, physicians struggle to interpret these models, and feel it is hard to trust them. In this paper, we carefully develop an accurate and interpretable AD diagnosis and progression detection model. This model provides physicians with accurate decisions along with a set of explanations for every decision. Specifically, the model integrates 11 modalities of 1048 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) real-world dataset: 294 cognitively normal, 254 stable mild cognitive impairment (MCI), 232 progressive MCI, and 268 AD. It is actually a two-layer model with random forest (RF) as classifier algorithm. In the first layer, the model carries out a multi-class classification for the early diagnosis of AD patients. In the second layer, the model applies binary classification to detect possible MCI-to-AD progression within three years from a baseline diagnosis. The performance of the model is optimized with key markers selected from a large set of biological and clinical measures. Regarding explainability, we provide, for each layer, global and instance-based explanations of the RF classifier by using the SHapley Additive exPlanations (SHAP) feature attribution framework. In addition, we implement 22 explainers based on decision trees and fuzzy rule-based systems to provide complementary justifications for every RF decision in each layer. Furthermore, these explanations are represented in natural language form to help physicians understand the predictions. The designed model achieves a cross-validation accuracy of 93.95% and an F1-score of 93.94% in the first layer, while it achieves a cross-validation accuracy of 87.08% and an F1-Score of 87.09% in the second layer. The resulting system is not only accurate, but also trustworthy, accountable, and medically applicable, thanks to the provided explanations which are broadly consistent with each other and with the AD medical literature. The proposed system can help to enhance the clinical understanding of AD diagnosis and progression processes by providing detailed insights into the effect of different modalities on the disease risk.
Brain is the controlling center of our body. With the advent of time, newer and newer brain diseases are being discovered. Thus, because of the variability of brain diseases, existing diagnosis or detection systems are becoming challenging and are still an open problem for research. Detection of brain diseases at an early stage can make a huge difference in attempting to cure them. In recent years, the use of artificial intelligence (AI) is surging through all spheres of science, and no doubt, it is revolutionizing the field of neurology. Application of AI in medical science has made brain disease prediction and detection more accurate and precise. In this study, we present a review on recent machine learning and deep learning approaches in detecting four brain diseases such as Alzheimer's disease (AD), brain tumor, epilepsy, and Parkinson's disease. 147 recent articles on four brain diseases are reviewed considering diverse machine learning and deep learning approaches, modalities, datasets etc. Twenty-two datasets are discussed which are used most frequently in the reviewed articles as a primary source of brain disease data. Moreover, a brief overview of different feature extraction techniques that are used in diagnosing brain diseases is provided. Finally, key findings from the reviewed articles are summarized and a number of major issues related to machine learning/deep learning-based brain disease diagnostic approaches are discussed. Through this study, we aim at finding the most accurate technique for detecting different brain diseases which can be employed for future betterment.
Healthcare sector is probably the most benefited from the applications of nanotechnology. The nanotechnology, in the forms of nanomedicine, nanoimplants, nanobiosensors along with the internet of nano things (IoNT), has the potential to bring a revolutionizing advancement in the field of medicine and healthcare services. The primary aim of this paper is to explore the clinical and medical possibilities of these different implementations of nanotechnology. This paper provides a comprehensive overview of nanotechnology, biosensors, nanobiosensors, and IoNT. Furthermore, multilevel taxonomies of nanotechnology, nanoparticles, biosensors, nanobiosensors, and nanozymes are presented. The potential medical and clinical applications of these technologies are discussed in details with several examples. This paper specifically focuses on IoNT and its role in healthcare. In addition to describing a general architecture of IoNT for healthcare, the communication architecture of the IoNT is also explained. The challenges in the successful realization of IoNT are also discussed critically, along with a special discussion on internet of bio-nano things (IoBNT) and its potential in making IoNT more compatible to human body.
Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT, hereafter abbreviated SCT) is a comprehensive medical terminology used for standardizing the storage, retrieval, and exchange of electronic health data. Some efforts have been made to capture the contents of SCT as Web Ontology Language (OWL), but these efforts have been hampered by the size and complexity of SCT. Our proposal here is to develop an upper-level ontology and to use it as the basis for defining the terms in SCT in a way that will support quality assurance of SCT, for example, by allowing consistency checks of definitions and the identification and elimination of redundancies in the SCT vocabulary. Our proposed upper-level SCT ontology (SCTO) is based on the Ontology for General Medical Science (OGMS). The SCTO is implemented in OWL 2, to support automatic inference and consistency checking. The approach will allow integration of SCT data with data annotated using Open Biomedical Ontologies (OBO) Foundry ontologies, since the use of OGMS will ensure consistency with the Basic Formal Ontology, which is the top-level ontology of the OBO Foundry. Currently, the SCTO contains 304 classes, 28 properties, 2400 axioms, and 1555 annotations. It is publicly available through the bioportal at . The resulting ontology can enhance the semantics of clinical decision support systems and semantic interoperability among distributed electronic health records. In addition, the populated ontology can be used for the automation of mobile health applications.
13 April 2020 in IEEE Transactions on Wireless Communications